Patient Preferences for Antithrombotic Treatment in Acute and Chronic Phases of Myocardial Infarction
- Location: Online
- Lecturer: Cathy Anne Pinto, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA & Tommi Tervonen, Patient-Centered Research, Evidera, a business unit of PPD, Switzerland
- Contact person: Carl Steinbeisser
PREFER partners are contributing data from their own patient preference studies. One of these case studies explored patient preferences for treatment following a myocardial infarction (a heart attack) and how they value the benefits and risks of antithrombotic treatment at the acute and chronic stages of heart disease. In this webinar, we describe the design of the study and its main results.
Antithrombotic treatments are used to prevent the risk of future ischemic events in patients following a myocardial infarction (heart attack). These drugs can be administered during emergency medical care in a hospital or after leaving the hospital when the patients’ condition is more stable. This webinar describes a study, conducted in collaboration with the IMI PREFER consortium, that aimed to understand patient preferences for benefits and risks for antithrombotic treatment throughout the acute and chronic stages of heart disease.
In this webinar, we will describe how the patient preference study was designed and its main results. We will then discuss what implications the results may have on the development of drugs to treat heart disease. Finally, we will show how the preference data may be combined with clinical data (trial data and real-world data) to understand how the treatment’s benefit-risk profile may be expected to vary in the real-world target population.